Literature DB >> 16402107

The attraction of chemokines as a target for specific anti-inflammatory therapy.

James E Pease1, Timothy J Williams.   

Abstract

Since the identification of the first chemotactic cytokines 20 years ago, the field has mushroomed, with the discovery of approximately 40 ligands, which interact with 20 different cell surface receptors. At the time of writing this review, a PubMed trawl using the word 'chemokine' will recover over 28,000 manuscripts. In this article, we will give a short history of the discovery of chemokines and provide examples of the potential for therapeutic targeting of the chemokine network in inflammatory disease.

Mesh:

Substances:

Year:  2006        PMID: 16402107      PMCID: PMC1760746          DOI: 10.1038/sj.bjp.0706475

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

Review 1.  Chemokines: a new classification system and their role in immunity.

Authors:  A Zlotnik; O Yoshie
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

2.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Authors:  T Dragic; A Trkola; D A Thompson; E G Cormier; F A Kajumo; E Maxwell; S W Lin; W Ying; S O Smith; T P Sakmar; J P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

Review 3.  Transduction of receptor signals by beta-arrestins.

Authors:  Robert J Lefkowitz; Sudha K Shenoy
Journal:  Science       Date:  2005-04-22       Impact factor: 47.728

4.  On the dimerization of CCR5.

Authors:  Julie Lemay; Stefano Marullo; Ralf Jockers; Marc Alizon; Anne Brelot
Journal:  Nat Immunol       Date:  2005-06       Impact factor: 25.606

Review 5.  Chemokine receptor internalization and intracellular trafficking.

Authors:  Nicole F Neel; Evemie Schutyser; Jiqing Sai; Guo-Huang Fan; Ann Richmond
Journal:  Cytokine Growth Factor Rev       Date:  2005-07-05       Impact factor: 7.638

6.  A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry.

Authors:  I Sabroe; M J Peck; B J Van Keulen; A Jorritsma; G Simmons; P R Clapham; T J Williams; J E Pease
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

Review 7.  Regulation of protein function by glycosaminoglycans--as exemplified by chemokines.

Authors:  T M Handel; Z Johnson; S E Crown; E K Lau; A E Proudfoot
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

8.  Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction.

Authors:  Z Li; H Jiang; W Xie; Z Zhang; A V Smrcka; D Wu
Journal:  Science       Date:  2000-02-11       Impact factor: 47.728

9.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.

Authors:  C C Bleul; M Farzan; H Choe; C Parolin; I Clark-Lewis; J Sodroski; T A Springer
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

10.  Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist.

Authors:  Filipa Lopes de Mendonça; Paula C A da Fonseca; Rhian M Phillips; José W Saldanha; Timothy J Williams; James E Pease
Journal:  J Biol Chem       Date:  2004-11-17       Impact factor: 5.157

View more
  26 in total

1.  The yin and yang of chemokine receptor activation.

Authors:  Graeme O'Boyle
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Chemokines as Therapeutic Targets to Improve Healing Efficiency of Chronic Wounds.

Authors:  Latha Satish
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

3.  CD192 gene variant and susceptibility to cervical cancer: a meta analysis.

Authors:  Yuying Chen; Xinli Liu; Min Chen; Jian Shen; Yanqi Lu; Lei Yu; Shouying Liu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  Induction of host chemotactic response by Encephalitozoon spp.

Authors:  Jeffrey Fischer; Jeffrey West; Nnenaya Agochukwu; Colby Suire; Hollie Hale-Donze
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

5.  Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists.

Authors:  Denis Sohy; Hideaki Yano; Patricia de Nadai; Eneko Urizar; Aude Guillabert; Jonathan A Javitch; Marc Parmentier; Jean-Yves Springael
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

6.  Down-modulation of primate lentiviral receptors by Nef proteins of simian immunodeficiency virus (SIV) of chimpanzees (SIVcpz) and related SIVs: implication for the evolutionary event at the emergence of SIVcpz.

Authors:  Yusuke Nakano; Kenta Matsuda; Rokusuke Yoshikawa; Eri Yamada; Naoko Misawa; Vanessa M Hirsch; Yoshio Koyanagi; Kei Sato
Journal:  J Gen Virol       Date:  2015-06-03       Impact factor: 3.891

7.  Chemokine expression by small sputum macrophages in COPD.

Authors:  Marion Frankenberger; Christiane Eder; Thomas P J Hofer; Irene Heimbeck; Kerstin Skokann; Gudrun Kassner; Norbert Weber; Winfried Möller; Loems Ziegler-Heitbrock
Journal:  Mol Med       Date:  2011-02-09       Impact factor: 6.354

8.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Authors:  L A Jopling; G F Watt; S Fisher; H Birch; S Coggon; M I Christie
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

9.  The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function.

Authors:  Jia Ni; Yi-Na Zhu; Xiang-Gen Zhong; Yu Ding; Li-Fei Hou; Xian-Kun Tong; Wei Tang; Shiro Ono; Yi-Fu Yang; Jian-Ping Zuo
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

10.  Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats.

Authors:  M M Barsante; T M Cunha; M Allegretti; F Cattani; F Policani; C Bizzarri; W L Tafuri; S Poole; F Q Cunha; R Bertini; M M Teixeira
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.